N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Sponsor: ORIC Pharmaceuticals • ClinicalTrials.gov ID: NCT05315700

Registry updated: 2026-09-04
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Interventions

  • ORIC-114 (Drug)
    ORIC-114 oral daily
  • Chemotherapy drug (Drug)
    21 days for up to 4 cycles

Eligibility criteria

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test 1. Part I Dose Escalation (CLOSED) Any solid tumor with * EGFR exon 20 insertion mutation * HER2 exon 20 insertion mutation * Atypical EGFR mutations (NSCLC only) (Appendix 8) * HER2 amplification or overexpression (HER2+) * Previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable 2. Part I Extension (ONGOING) * Cohort IA: Patients with HER2+ breast cancer previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable * Cohort IB: NSCLC patients with EGFR exon 20 insertion mutation previously treated with chemotherapy and amivantamab * Cohort IC: Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutation * Cohort ID: Treatment-naïve NSCLC patients with EGFR atypical mutations 3. Part II Dose Optimization (ONGOING): NSCLC patients with * Cohort IIA: EGFR exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to an EGFR exon 20 targeted agent, ie, must have declined or be ineligible for all available exon 20 targeted therapies with proven benefit * Cohort IIB: HER2 exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to a HER2 exon 20 targeted TKI * Cohort IIC: Atypical EGFR mutation, patients may have received a prior EGFR TKI * Agreement and ability to undergo pretreatment biopsy * Measurable disease according to RECIST 1.1 * CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic * ECOG performance status of 0 or 1 * Adequate organ function Exclusion Criteria: * Known EGFR T790M mutation * Leptomeningeal disease and spinal cord compression \-- Except if LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the Investigator; the subject must be free of neurological symptoms of LMD * History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months * Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD * Known, symptomatic human immunodeficiency virus (HIV) infection * Known active infection requiring treatment or history of hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients positive for HBsAg but normal HBV DNA level are allowed. * Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes * Any other concurrent serious uncontrolled medical, psychological, or addictive conditions

Conditions

Solid Tumors

Locations

  • City of Hope — Duarte, California, United States
  • City of Hope — Huntington Beach, California, United States
  • City of Hope — Irvine, California, United States
  • City of Hope — Long Beach, California, United States
  • University of California, San Francisco — San Francisco, California, United States
  • Yale Cancer Center — New Haven, Connecticut, United States
  • Georgetown University — Washington D.C., District of Columbia, United States
  • Mayo Clinic — Jacksonville, Florida, United States
  • Moffitt Cancer Center — Tampa, Florida, United States
  • Northwestern University — Chicago, Illinois, United States
  • Dana Farber Cancer Institute — Boston, Massachusetts, United States
  • Mayo Clinic — Rochester, Minnesota, United States
  • NYU Langone Health Perlmutter Cancer Center — New York, New York, United States
  • Duke Cancer Institute — Durham, North Carolina, United States
  • University of Pennsylvania — Philadelphia, Pennsylvania, United States
  • Spartanburg Regional Healthcare System — Spartanburg, South Carolina, United States
  • Next Oncology — Fairfax, Virginia, United States
  • Chris O'Brien Lifehouse — Camperdown, Australia
  • Peter MacCallum Cancer Centre — Melbourne, Australia
  • One Clinical Research, Hollywood Medical Centre — Nedlands, Australia
  • Sydney Adventist Health — Sydney, Australia
  • Princess Margaret Cancer Centre — Toronto, Ontario, Canada
  • The Chinese University of Hong Kong — Shatin, Hong Kong
  • Sultan Ahmad Shah Medical Centre at International Islamic University Malaysia (IIUM) — Kuantan, Pahang, Malaysia
  • Pulau Pinang Hospital — George Town, Pulau Pinang, Malaysia
  • Sarawak General Hospital (SGH) — Kuching, Sarawak, Malaysia
  • Hospital Kuala Lumpur — Kuala Lumpur, Malaysia
  • University of Malaya Medical Center (UMMC) — Kuala Lumpur, Malaysia
  • Medical University of Gdańsk — Gdansk, Poland
  • Chungbuk University Hospital — Cheongju-si, South Korea
  • National Cancer Center — Goyang-si, South Korea
  • Catholic University of Korea, St, Vincent Hospital — Gyeonggi-do, South Korea
  • Gachon University Hospital — Incheon, South Korea
  • Seoul National Bundang Hospital — Seongnam-si, South Korea
  • Asan Medical Center — Seoul, South Korea
  • Samsung Medical Center — Seoul, South Korea
  • Severance Hospital, Yonsei University Health System — Seoul, South Korea
  • NEXT Oncology - Barcelona — Barcelona, Spain
  • Vall d'Hebron Institute of Oncology (VHIO) — Barcelona, Spain
  • NEXT Oncology - Madrid — Madrid, Spain
  • National Taiwan University Hospital — Taipei, Taiwan
  • The Christie NHS Foundation Trust — Manchester, England, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record